DC-CIK + paclitaxel + cisplatin

DC-CIK + paclitaxel + cisplatin is a combination regimen for cancer treatment that integrates three components: - **DC-CIK** (dendritic cell-cytokine-induced killer cell therapy) is an adoptive cell therapy combining dendritic cells (professional antigen-presenting cells) and cytokine-induced killer (CIK) cells (cytotoxic lymphocytes with both T cell and NK cell–like activity). DC-CIK therapy enhances the immune response against tumors via increased presentation of tumor antigens to T cells and induction of direct and MHC-unrestricted cytotoxicity, along with cytokine release (notably IFN-γ and IL-12). - **Paclitaxel** is a microtubule-stabilizing small molecule chemotherapeutic agent that inhibits cell division, leading to mitotic arrest and apoptosis in cancer cells. - **Cisplatin** is a platinum-based small molecule chemotherapy agent that crosslinks DNA, promoting cell death in rapidly dividing tumor cells. This combination is under investigation for improved anti-tumor efficacy, particularly leveraging DC-CIK’s potential for immune activation and residual disease clearance, alongside the cytotoxic effects of chemotherapy. The comprehensive approach aims to both debulk the tumor and promote lasting immunological surveillance and tumor elimination[1][2][3][5].

Other names

dendritic cell-cytokine-induced killer cell immunotherapy + paclitaxel + cisplatin